Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model

Autoimmunity

Volumn 48, Issue 7, 2015, Pages 460-470

  Atkinson, Sara M ^a,b   Nansen, Anneline ^a   Usher, Pernille A ^a   Sondergaard, Bodil Cecilie ^a   Mackay, Charles R ^c   Friedrichsen, Birgitte ^a   Chang, Chih Chuan ^d   Tang, Renhong ^d   Skov, Søren ^b   Haase, Claus ^a   Hornum, Lars ^a  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c MONASH UNIVERSITY   (Australia)

^d SIBS Novo Nordisk Translational Research Centre for PreDiabetes   (China)

Author keywords

Bone erosion; C5a; complement; neutrophils; rheumatoid arthritis

Indexed keywords

COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTACTIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IGG2A.1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ANTIGEN ANTIBODY COMPLEX; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BONE EROSION; CARTILAGE DEGENERATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DELAYED TYPE HYPERSENSITIVITY ARTHRITIS; DISEASE ACTIVITY; FEMALE; HISTOPATHOLOGY; JOINT CAVITY; LEUKOCYTE ACTIVATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OSSIFICATION; PAW; PAW EDEMA; PAW TISSUE; RECEPTOR BLOCKING; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SYNOVITIS; SYNOVIUM; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; EDEMA; GENE EXPRESSION; GENETICS; HINDLIMB; HUMAN; HYPERSENSITIVITY, DELAYED; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; NEUTROPHIL; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGEN-ANTIBODY COMPLEX; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; COMPLEMENT C5A; DISEASE MODELS, ANIMAL; EDEMA; FEMALE; GENE EXPRESSION; HINDLIMB; HUMANS; HYPERSENSITIVITY, DELAYED; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; NEUTROPHILS; RECEPTOR, ANAPHYLATOXIN C5A; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84947027223     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2015.1031888     Document Type: Article

References (49)

1. Sturfelt, G., and L. Truedsson. 2012. Complement in the immunopathogenesis of rheumatic disease. Nat. Rev. Rheumatol. 8: 458-468.
2. Chen, M., M. R. Daha, and C. G. Kallenberg. 2010. The complement system in systemic autoimmune disease. J. Autoimmun. 34: J276-J286.
3. Okroj, M., D. Heinegård, R. Holmdahl, and A. M. Blom. 2007. Rheumatoid arthritis and the complement system. Ann. Med. 39: 517-530.
4. Jose, P. J., I. K. Moss, R. N. Maini, and T. J. Williams. 1990. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann. Rheum. Dis. 49: 747-752.
5. Yuan, G., J. Wei, J. Zhou, et al. 2003. Expression of C5aR (CD88) of synoviocytes isolated from patients with rheumatoid arthritis and osteoarthritis. Chin. Med. J. (Engl.) 116: 1408-1412.
6. Guo, R. F., and P. A. Ward. 2004. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23: 821-852.
7. Wetsel, R. A. 1995. Expression of the complement C5a anaphylatoxin receptor (C5aR) on non-myeloid cells. Immunol. Lett. 44: 183-187.
8. Ignatius, A., P. Schoengraf, L. Kreja, et al. 2011. Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1β. J. Cell. Biochem. 112: 2594-2605.
9. Strainic, M. G., J. Liu, D. Huang, et al. 2008. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28: 425-435.
10. Lalli, P. N., M. G. Strainic, M. Yang, et al. 2008. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 112: 1759-1766.
11. DiScipio, R. G., I. U. Schraufstatter, L. Sikora, et al 2006. C5a mediates secretion and activation of matrix metalloproteinase 9 from human eosinophils and neutrophils. Int. Immunopharmacol. 6: 1109-1118.
12. Kolaczkowska, E., and P. Kubes. 2013. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13: 159-175.
13. Zhou, W. 2012. The new face of anaphylatoxins in immune regulation. Immunobiology 217: 225-234.
14. Gonzalez, J. M., C. W. Franzke, F. Yang, et al. 2011. Complement activation triggers metalloproteinases release inducing cervical remodeling and preterm birth in mice. Am. J. Pathol. 179: 838-849.
15. Guo, R. F., L. Sun, H. Gao, et al. 2006. In vivo regulation of neutrophil apoptosis by C5a during sepsis. J. Leukoc. Biol. 80: 1575-1583.
16. Kessel, C., K. S. Nandakumar, F. B. Peters, et al. 2014. A single functional group substitution in c5a breaks B cell and T cell tolerance and protects against experimental arthritis. Arthritis Rheumatol. 66: 610-621.
17. Woodruff, T. M., A. J. Strachan, N. Dryburgh, et al. 2002. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum. 46: 2476-2485.
18. Banda, N. K., S. Hyatt, A. H. Antonioli, et al. 2012. Role of C3a receptors, C5a receptors, and complement protein c6 deficiency in collagen antibody-induced arthritis in mice. J. Immunol. 188: 1469-1478.
19. Grant, E. P., D. Picarella, T. Burwell, et al. 2002. Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J. Exp. Med. 196: 1461-1471.
20. Hashimoto, M., K. Hirota, H. Yoshitomi, et al. 2010. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J. Exp. Med. 207: 1135-1143.
21. Sadik, C. D., N. D. Kim, Y. Iwakura, and A. D. Luster. 2012. Neutrophils orchestrate their own recruitment in murine arthritis through C5aR and FcγR signaling. Proc. Natl. Acad. Sci. 109: E3177-E3185.
22. Lee, H., D. Zahra, A. Vogelzang, et al. 2006. Human C5aR knockin mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies. Nat. Biotech. 24: 1279-1284.
23. Andersson, C., C. S. Wenander, P. A. Usher, et al. 2014. Rapidonset clinical and mechanistic effects of anti-C5aR treatment in the mouse collagen-induced arthritis model. Clin. Exp. Immunol. 177: 219-233.
24. Atkinson, S. M., P. A. Usher, P. H. Kvist, et al. 2012. Establishment and characterization of a sustained delayed-type hypersensitivity model with arthritic manifestations in C57BL/6J mice. Arthritis Res. Ther. 14: R134.
25. Goldschmidt, T. J., M. Andersson, V. Malmström, and R. Holmdahl. 1992. Activated type II collagen reactive T cells are not eliminated by in vivo anti-CD4 treatment: implications for therapeutic approaches on autoimmune arthritis. Immunobiology 184: 359-371.
26. Gabay, C., C. Lamacchia, and G. Palmer. 2010. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 6: 232-241.
27. Shushakova, N., J. Skokowa, J. Schulman, et al. 2002. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex-induced lung disease. J. Clin. Invest. 110: 1823-1830.
28. Naik, N., E. Giannini, L. Brouchon, and F. Boulay. 1997. Internalization and recycling of the C5a anaphylatoxin receptor: evidence that the agonist-mediated internalization is modulated by phosphorylation of the C-terminal domain. J. Cell. Sci. 110: 2381-2390.
29. Chou, R. C., N. D. Kim, C. D. Sadik, et al. 2010. Lipid-cytokinechemokine cascade drives neutrophil recruitment in a murine model of inflammatory arthritis. Immunity 33: 266-278.
30. Monach, P. A., P. A. Nigrovic, M. Chen, et al. 2010. Neutrophils in a mouse model of autoantibody-mediated arthritis: critical producers of Fc receptor gamma, the receptor for C5a, and lymphocyte function-associated antigen 1. Arthritis Rheum. 62: 753-764.
31. Nigrovic, P. A., B. A. Binstadt, P. A. Monach, et al. 2007. Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc. Natl. Acad. Sci. USA 104: 2325-2330.
32. Biedermann, T., M. Kneilling, R. Mailhammer, et al. 2000. Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J. Exp. Med. 192: 1441-1452.
33. Happonen, K. E., D. Heinegard, T. Saxne, and A. M. Blom. 2012. Interactions of the complement system with molecules of extracellular matrix: relevance for joint diseases. Immunobiology 217: 1088-1096.
34. Matsumoto, I., M. Maccioni, D. M. Lee, et al. 2002. How antibodies to a ubiquitous cytoplasmic enzyme may provoke jointspecific autoimmune disease. Nat. Immunol. 3: 360-365.
35. De Filippo, K., A. Dudeck, M. Hasenberg, et al. 2013. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood 121: 4930-4937.
36. Grespan, R., S. Y. Fukada, H. P. Lemos, et al. 2008. CXCR2-specific chemokines mediate leukotriene B4-dependent recruitment of neutrophils to inflamed joints in mice with antigen-induced arthritis. Arthritis Rheum. 58: 2030-2040.
37. Blaschke, S., P. Middel, B. G. Dorner, et al. 2003. Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis. Arthritis Rheum. 48: 1858-1872.
38. von Vietinghoff S., and K. Ley. 2008. Homeostatic regulation of blood neutrophil counts. J. Immunol. 181: 5183-5188.
39. Bosmann, M., M. D. Haggadone, F. S. Zetoune, et al. 2013. The interaction between C5a and both C5aR and C5L2 receptors is required for production of G-CSF during acute inflammation. Eur. J. Immunol. 43: 1907-1913.
40. Riedemann, N. C., R. Guo, T. J. Hollmann, et al. 2004. Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. FASEB J. 18: 370-372.
41. Scholz, W., M. R. McClurg, G. J. Cardenas, et al. 1990. C5amediated release of interleukin 6 by human monocytes. Clin. Immunol. Immunopathol. 57: 297-307.
42. Takayanagi, H. 2012. New developments in osteoimmunology. Nat. Rev. Rheumatol. 8: 684-689.
43. Chao, C. C., S. J. Chen, I. E. Adamopoulos, et al. 2010. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 44: 243-252.
44. Yoo, S. A., S. K. Kwok, and W. U. Kim. 2008. Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators. Inflamm. 2008: 129873.
45. Marrelli, A., P. Cipriani, V. Liakouli, et al. 2011. Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun. Rev. 10: 595-598.
46. Malemud, C. J. 2007. Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. Clin. Chim. Acta 375: 10-19.
47. Szekanecz, Z., T. Besenyei, G. Paragh, and A. E. Koch. 2009. Angiogenesis in rheumatoid arthritis. Autoimmunity 42: 563-573.
48. Ahmed, S., S. Riegsecker, M. Beamer, et al. 2013. Largazole, a class I histone deacetylase inhibitor, enhances TNFα-induced ICAM-1 and VCAM-1 expression in rheumatoid arthritis synovial fibroblasts. Toxicol. Appl. Pharm. 270: 87-96.
49. Heeger, P. S., and C. Kemper. 2012. Novel roles of complement in T effector cell regulation. Immunobiology 217: 216-224.